Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dynamic Changes in Circulating Tumour Cells Protein Expression
Sponsor: Matteo's Friends
Summary
This multicenter study, randomized, controlled of blood-based biomarker-driven targhet therapy. Patients were selectedm( at Hospital San Giovanni and Celio in Rome) according to CTCs results ( CTCs-guided managment performed at University Magna Graecia) or managed by the treating clinician according to standard pathological criteria (standard management). The participants were assigned to trial groups with the use of block randomization stratified according to the enrolling center location metropolitan) and tumor stage (T3 or T4).
Official title: Dynamic Changes in RAS Gene Status and HER2 Expression in Circulating Tumour Cells: a Phase II Trial
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2019-01-14
Completion Date
2027-12-18
Last Updated
2024-03-18
Healthy Volunteers
Yes
Conditions
Interventions
panitumumab (EGFR inhibitors)
Chemotherapy treatment includes anti-EGFR biologics such as cetuximab or panitumumab, antiangiogenic drugs such as bevacizumab or aflibercept. The indication to treat depends from the presence of CTCs analysed for Ras mutation and HER2 expression
Locations (1)
Natalia Malara
Germaneto, Italy